ESTRO 2025 - Abstract Book

S2123

Clinical - Urology

ESTRO 2025

completely or partially resected, or a biopsy of the tumor was performed. Local recurrence was assessed using cystoscopy. Toxicity was evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Quality of life was assessed using Patient-Reported Outcomes (PRO), (EQ-5D, global health status/QoL, and fatigue global health/QoL) at baseline and at 3, 6, 12, and 24 months after radiotherapy Results: From March 2021 to January 2024, 43 patients were enrolled. Table 1 show their baseline characteristics. The patients were ineligible for cystectomy, long course radiotherapy or chemotherapy. Disease stages included T1 T3N0-N2M0. The majority of the patients (40) completed all six fractions of radiotherapy. The median follow-up time was 9.6 month. During follow up, 22 (51%) patients died. The median OS was 12.5 months (1.5-31 months). The 2 years OS was 34%, similar to what was reported by Hafeez et al 2 . After treatment, 31 (72%) patients underwent cystoscopy as response evaluation and local control was achieved in 21 (68%) of those patients. Table 2 shows the frequency and grades of the toxicities observed. PRO data showed a clinical relevant decrease in the self-reported quality of life after 6 months. The fatigue worsened after 3 months. The median OS was 3-6 months lower compared to the reported survival in previously conducted studies 1,2 . This difference may be due to the inclusion of patients with more advanced disease, including those with lymph node metastases (21%) and those requiring catheter use (63%).